These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28617852)

  • 1. Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.
    Zhang W; Su J; Xu H; Yu S; Liu Y; Zhang Y; Sun L; Yue Y; Zhou X
    PLoS One; 2017; 12(6):e0179672. PubMed ID: 28617852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of pyruvate dehydrogenase kinase‑1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming.
    Xu H; He Y; Ma J; Zhao Y; Liu Y; Sun L; Su J
    Int J Oncol; 2020 Sep; 57(3):733-742. PubMed ID: 32705170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides as pyruvate dehydrogenase kinase 1 (PDK1) inhibitors to reduce the growth of cancer cells.
    Zhang SL; Zhang W; Yang Z; Hu X; Tam KY
    Eur J Pharm Sci; 2017 Dec; 110():87-92. PubMed ID: 28347773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anemone rivularis inhibits pyruvate dehydrogenase kinase activity and tumor growth.
    Chung TW; Lee JH; Choi HJ; Park MJ; Kim EY; Han JH; Jang SB; Lee SO; Lee SW; Hang J; Yi LW; Ha KT
    J Ethnopharmacol; 2017 May; 203():47-54. PubMed ID: 28341246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
    Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
    Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system.
    Goetze K; Fabian CG; Siebers A; Binz L; Faber D; Indraccolo S; Nardo G; Sattler UG; Mueller-Klieser W
    Cell Oncol (Dordr); 2015 Oct; 38(5):377-85. PubMed ID: 26288178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics.
    Zhang W; Hu X; Chakravarty H; Yang Z; Tam KY
    ACS Comb Sci; 2018 Nov; 20(11):660-671. PubMed ID: 30350563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
    Wu DM; Wang YJ; Fan SH; Zhang ZF; Shan Q; Lu J; Chen GQ; Zheng YL
    Eur J Med Chem; 2019 Feb; 164():252-262. PubMed ID: 30597326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ilimaquinone Induces the Apoptotic Cell Death of Cancer Cells by Reducing Pyruvate Dehydrogenase Kinase 1 Activity.
    Kwak CH; Jin L; Han JH; Han CW; Kim E; Cho M; Chung TW; Bae SJ; Jang SB; Ha KT
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A small molecule compound inhibits AKT pathway in ovarian cancer cell lines.
    Tang HJ; Jin X; Wang S; Yang D; Cao Y; Chen J; Gossett DR; Lin J
    Gynecol Oncol; 2006 Feb; 100(2):308-17. PubMed ID: 16209885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect.
    Zhang W; Zhang SL; Hu X; Tam KY
    Eur J Pharm Sci; 2017 Dec; 110():93-100. PubMed ID: 28450154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.
    Nagashima K; Shumway SD; Sathyanarayanan S; Chen AH; Dolinski B; Xu Y; Keilhack H; Nguyen T; Wiznerowicz M; Li L; Lutterbach BA; Chi A; Paweletz C; Allison T; Yan Y; Munshi SK; Klippel A; Kraus M; Bobkova EV; Deshmukh S; Xu Z; Mueller U; Szewczak AA; Pan BS; Richon V; Pollock R; Blume-Jensen P; Northrup A; Andersen JN
    J Biol Chem; 2011 Feb; 286(8):6433-48. PubMed ID: 21118801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
    Chao TK; Huang TS; Liao YP; Huang RL; Su PH; Shen HY; Lai HC; Wang YC
    PLoS One; 2017; 12(7):e0182166. PubMed ID: 28753677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1.
    Zhang SL; Yang Z; Hu X; Chakravarty H; Tam KY
    Eur J Pharm Sci; 2018 Oct; 123():43-55. PubMed ID: 30012506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
    Fang A; Luo H; Liu L; Fan H; Zhou Y; Yao Y; Zhang Y
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5450-5453. PubMed ID: 29150396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: A potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions.
    Sradhanjali S; Tripathy D; Rath S; Mittal R; Reddy MM
    PLoS One; 2017; 12(5):e0177744. PubMed ID: 28505181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?
    Zhang W; Zhang SL; Hu X; Tam KY
    Int J Biol Sci; 2015; 11(12):1390-400. PubMed ID: 26681918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification.
    Sun W; Xie Z; Liu Y; Zhao D; Wu Z; Zhang D; Lv H; Tang S; Jin N; Jiang H; Tan M; Ding J; Luo C; Li J; Huang M; Geng M
    Cancer Res; 2015 Nov; 75(22):4923-36. PubMed ID: 26483203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDK1 inhibition is a novel therapeutic target in multiple myeloma.
    Fujiwara S; Kawano Y; Yuki H; Okuno Y; Nosaka K; Mitsuya H; Hata H
    Br J Cancer; 2013 Jan; 108(1):170-8. PubMed ID: 23321518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
    Ai Z; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.